APO RESEARCH · REPORT
Contract Pharmaceutical Manufacturing
Contract Pharmaceutical Manufacturing refers to accept commissioned from pharmaceutical companies, provide the service about API production, agent production, packaging and son on which required for pharmaceutical manufacturing.
Product & engineering
Understand the product.
Contract Pharmaceutical Manufacturing refers to accept commissioned from pharmaceutical companies, provide the service about API production, agent production, packaging and son on which required for pharmaceutical manufacturing.
Selected research
Market Analysis & Forecast
Global Contract Pharmaceutical Manufacturing Market Analysis and Forecast 2026-2032
Market perspective
Contract Pharmaceutical Manufacturing refers to accept commissioned from pharmaceutical companies, provide the service about API production, agent production, packaging and son on which required for pharmaceutical manufacturing.
Global Contract Pharmaceutical Manufacturing key players include Catalent, Thermo Fisher Scientific, Lonza, Boehringer Ingelheim, Fareva, etc. Global top five players hold a share about 10%.
North America is the largest market, with a share about 30%, followed by Europe and China, having a total share about 30 percent.
Read the full market overview
In terms of product, API is the largest segment, with a share about 75%. And in terms of application, the largest application is Large Enterprise, followed by Small Medium Enterprise.
Report Includes
This report presents an overview of global market for Contract Pharmaceutical Manufacturing, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Contract Pharmaceutical Manufacturing, also provides the revenue of main regions and countries. Of the upcoming market potential for Contract Pharmaceutical Manufacturing, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Contract Pharmaceutical Manufacturing revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Contract Pharmaceutical Manufacturing market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Contract Pharmaceutical Manufacturing revenue, projected growth trends, production technology, application and end-user industry.
Contract Pharmaceutical Manufacturing Segment by Company
Catalent
DPx
Lonza
Piramal Healthcare
Aenova
Jubilant
Famar
Boehringer Ingelheim
Fareva Holding
AbbVie
Nipro Corp
Vetter
Sopharma
DPT Laboratories
Recipharm
NextPharma
Dishman
Aesica
Contract Pharmaceutical Manufacturing Segment by Type
Oral
Injectable
API
Other
Contract Pharmaceutical Manufacturing Segment by Application
Large Enterprise
Small Medium Enterprise
Contract Pharmaceutical Manufacturing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Contract Pharmaceutical Manufacturing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Contract Pharmaceutical Manufacturing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Contract Pharmaceutical Manufacturing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Contract Pharmaceutical Manufacturing in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Contract Pharmaceutical Manufacturing company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Contract Pharmaceutical Manufacturing revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injectable
- API
- Other
Applications
- Large Enterprise
- Small Medium Enterprise
Companies covered
- Catalent
- DPx
- Lonza
- Piramal Healthcare
- Aenova
- Jubilant
- Famar
- Boehringer Ingelheim
- Fareva Holding
- AbbVie
- Nipro Corp
- Vetter
- Sopharma
- DPT Laboratories
- Recipharm
- NextPharma
- Dishman
- Aesica
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Contract Pharmaceutical Manufacturing Market by Type
- 1.2.1 Global Contract Pharmaceutical Manufacturing Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Oral
- 1.2.3 Injectable
- 1.2.4 API
- 1.2.5 Other
- 1.3 Contract Pharmaceutical Manufacturing Market by Application
- 1.3.1 Global Contract Pharmaceutical Manufacturing Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Large Enterprise
- 1.3.3 Small Medium Enterprise
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Contract Pharmaceutical Manufacturing Market Dynamics
- 2.1 Contract Pharmaceutical Manufacturing Industry Trends
- 2.2 Contract Pharmaceutical Manufacturing Industry Drivers
- 2.3 Contract Pharmaceutical Manufacturing Industry Opportunities and Challenges
- 2.4 Contract Pharmaceutical Manufacturing Industry Restraints
3 Global Growth Perspective
- 3.1 Global Contract Pharmaceutical Manufacturing Market Perspective (2021-2032)
- 3.2 Global Contract Pharmaceutical Manufacturing Growth Trends by Region
- 3.2.1 Global Contract Pharmaceutical Manufacturing Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Contract Pharmaceutical Manufacturing Market Size by Region (2021-2026)
- 3.2.3 Global Contract Pharmaceutical Manufacturing Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Contract Pharmaceutical Manufacturing Revenue by Players
- 4.1.1 Global Contract Pharmaceutical Manufacturing Revenue by Players (2021-2026)
- 4.1.2 Global Contract Pharmaceutical Manufacturing Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Contract Pharmaceutical Manufacturing Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Contract Pharmaceutical Manufacturing Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Contract Pharmaceutical Manufacturing Key Players Headquarters & Area Served
- 4.4 Global Contract Pharmaceutical Manufacturing Players, Product Type & Application
- 4.5 Global Contract Pharmaceutical Manufacturing Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Contract Pharmaceutical Manufacturing Market CR5 and HHI
- 4.6.3 2025 Contract Pharmaceutical Manufacturing Tier 1, Tier 2, and Tier 3
5 Contract Pharmaceutical Manufacturing Market Size by Type
- 5.1 Global Contract Pharmaceutical Manufacturing Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Contract Pharmaceutical Manufacturing Revenue by Type (2021-2032)
- 5.3 Global Contract Pharmaceutical Manufacturing Revenue Market Share by Type (2021-2032)
6 Contract Pharmaceutical Manufacturing Market Size by Application
- 6.1 Global Contract Pharmaceutical Manufacturing Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Contract Pharmaceutical Manufacturing Revenue by Application (2021-2032)
- 6.3 Global Contract Pharmaceutical Manufacturing Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Catalent
- 7.1.1 Catalent Company Information
- 7.1.2 Catalent Business Overview
- 7.1.3 Catalent Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.1.4 Catalent Contract Pharmaceutical Manufacturing Product Portfolio
- 7.1.5 Catalent Recent Developments
- 7.2 DPx
- 7.2.1 DPx Company Information
- 7.2.2 DPx Business Overview
- 7.2.3 DPx Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.2.4 DPx Contract Pharmaceutical Manufacturing Product Portfolio
- 7.2.5 DPx Recent Developments
- 7.3 Lonza
- 7.3.1 Lonza Company Information
- 7.3.2 Lonza Business Overview
- 7.3.3 Lonza Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.3.4 Lonza Contract Pharmaceutical Manufacturing Product Portfolio
- 7.3.5 Lonza Recent Developments
- 7.4 Piramal Healthcare
- 7.4.1 Piramal Healthcare Company Information
- 7.4.2 Piramal Healthcare Business Overview
- 7.4.3 Piramal Healthcare Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.4.4 Piramal Healthcare Contract Pharmaceutical Manufacturing Product Portfolio
- 7.4.5 Piramal Healthcare Recent Developments
- 7.5 Aenova
- 7.5.1 Aenova Company Information
- 7.5.2 Aenova Business Overview
- 7.5.3 Aenova Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.5.4 Aenova Contract Pharmaceutical Manufacturing Product Portfolio
- 7.5.5 Aenova Recent Developments
- 7.6 Jubilant
- 7.6.1 Jubilant Company Information
- 7.6.2 Jubilant Business Overview
- 7.6.3 Jubilant Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.6.4 Jubilant Contract Pharmaceutical Manufacturing Product Portfolio
- 7.6.5 Jubilant Recent Developments
- 7.7 Famar
- 7.7.1 Famar Company Information
- 7.7.2 Famar Business Overview
- 7.7.3 Famar Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.7.4 Famar Contract Pharmaceutical Manufacturing Product Portfolio
- 7.7.5 Famar Recent Developments
- 7.8 Boehringer Ingelheim
- 7.8.1 Boehringer Ingelheim Company Information
- 7.8.2 Boehringer Ingelheim Business Overview
- 7.8.3 Boehringer Ingelheim Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.8.4 Boehringer Ingelheim Contract Pharmaceutical Manufacturing Product Portfolio
- 7.8.5 Boehringer Ingelheim Recent Developments
- 7.9 Fareva Holding
- 7.9.1 Fareva Holding Company Information
- 7.9.2 Fareva Holding Business Overview
- 7.9.3 Fareva Holding Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.9.4 Fareva Holding Contract Pharmaceutical Manufacturing Product Portfolio
- 7.9.5 Fareva Holding Recent Developments
- 7.10 AbbVie
- 7.10.1 AbbVie Company Information
- 7.10.2 AbbVie Business Overview
- 7.10.3 AbbVie Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.10.4 AbbVie Contract Pharmaceutical Manufacturing Product Portfolio
- 7.10.5 AbbVie Recent Developments
- 7.11 Nipro Corp
- 7.11.1 Nipro Corp Company Information
- 7.11.2 Nipro Corp Business Overview
- 7.11.3 Nipro Corp Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.11.4 Nipro Corp Contract Pharmaceutical Manufacturing Product Portfolio
- 7.11.5 Nipro Corp Recent Developments
- 7.12 Vetter
- 7.12.1 Vetter Company Information
- 7.12.2 Vetter Business Overview
- 7.12.3 Vetter Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.12.4 Vetter Contract Pharmaceutical Manufacturing Product Portfolio
- 7.12.5 Vetter Recent Developments
- 7.13 Sopharma
- 7.13.1 Sopharma Company Information
- 7.13.2 Sopharma Business Overview
- 7.13.3 Sopharma Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.13.4 Sopharma Contract Pharmaceutical Manufacturing Product Portfolio
- 7.13.5 Sopharma Recent Developments
- 7.14 DPT Laboratories
- 7.14.1 DPT Laboratories Company Information
- 7.14.2 DPT Laboratories Business Overview
- 7.14.3 DPT Laboratories Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.14.4 DPT Laboratories Contract Pharmaceutical Manufacturing Product Portfolio
- 7.14.5 DPT Laboratories Recent Developments
- 7.15 Recipharm
- 7.15.1 Recipharm Company Information
- 7.15.2 Recipharm Business Overview
- 7.15.3 Recipharm Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.15.4 Recipharm Contract Pharmaceutical Manufacturing Product Portfolio
- 7.15.5 Recipharm Recent Developments
- 7.16 NextPharma
- 7.16.1 NextPharma Company Information
- 7.16.2 NextPharma Business Overview
- 7.16.3 NextPharma Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.16.4 NextPharma Contract Pharmaceutical Manufacturing Product Portfolio
- 7.16.5 NextPharma Recent Developments
- 7.17 Dishman
- 7.17.1 Dishman Company Information
- 7.17.2 Dishman Business Overview
- 7.17.3 Dishman Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.17.4 Dishman Contract Pharmaceutical Manufacturing Product Portfolio
- 7.17.5 Dishman Recent Developments
- 7.18 Aesica
- 7.18.1 Aesica Company Information
- 7.18.2 Aesica Business Overview
- 7.18.3 Aesica Contract Pharmaceutical Manufacturing Revenue and Gross Margin (2021-2026)
- 7.18.4 Aesica Contract Pharmaceutical Manufacturing Product Portfolio
- 7.18.5 Aesica Recent Developments
8 North America
- 8.1 North America Contract Pharmaceutical Manufacturing Revenue (2021-2032)
- 8.2 North America Contract Pharmaceutical Manufacturing Revenue by Type (2021-2032)
- 8.2.1 North America Contract Pharmaceutical Manufacturing Revenue by Type (2021-2026)
- 8.2.2 North America Contract Pharmaceutical Manufacturing Revenue by Type (2027-2032)
- 8.3 North America Contract Pharmaceutical Manufacturing Revenue Share by Type (2021-2032)
- 8.4 North America Contract Pharmaceutical Manufacturing Revenue by Application (2021-2032)
- 8.4.1 North America Contract Pharmaceutical Manufacturing Revenue by Application (2021-2026)
- 8.4.2 North America Contract Pharmaceutical Manufacturing Revenue by Application (2027-2032)
- 8.5 North America Contract Pharmaceutical Manufacturing Revenue Share by Application (2021-2032)
- 8.6 North America Contract Pharmaceutical Manufacturing Revenue by Country
- 8.6.1 North America Contract Pharmaceutical Manufacturing Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Contract Pharmaceutical Manufacturing Revenue by Country (2021-2026)
- 8.6.3 North America Contract Pharmaceutical Manufacturing Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Contract Pharmaceutical Manufacturing Revenue (2021-2032)
- 9.2 Europe Contract Pharmaceutical Manufacturing Revenue by Type (2021-2032)
- 9.2.1 Europe Contract Pharmaceutical Manufacturing Revenue by Type (2021-2026)
- 9.2.2 Europe Contract Pharmaceutical Manufacturing Revenue by Type (2027-2032)
- 9.3 Europe Contract Pharmaceutical Manufacturing Revenue Share by Type (2021-2032)
- 9.4 Europe Contract Pharmaceutical Manufacturing Revenue by Application (2021-2032)
- 9.4.1 Europe Contract Pharmaceutical Manufacturing Revenue by Application (2021-2026)
- 9.4.2 Europe Contract Pharmaceutical Manufacturing Revenue by Application (2027-2032)
- 9.5 Europe Contract Pharmaceutical Manufacturing Revenue Share by Application (2021-2032)
- 9.6 Europe Contract Pharmaceutical Manufacturing Revenue by Country
- 9.6.1 Europe Contract Pharmaceutical Manufacturing Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Contract Pharmaceutical Manufacturing Revenue by Country (2021-2026)
- 9.6.3 Europe Contract Pharmaceutical Manufacturing Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Contract Pharmaceutical Manufacturing Revenue (2021-2032)
- 10.2 China Contract Pharmaceutical Manufacturing Revenue by Type (2021-2032)
- 10.2.1 China Contract Pharmaceutical Manufacturing Revenue by Type (2021-2026)
- 10.2.2 China Contract Pharmaceutical Manufacturing Revenue by Type (2027-2032)
- 10.3 China Contract Pharmaceutical Manufacturing Revenue Share by Type (2021-2032)
- 10.4 China Contract Pharmaceutical Manufacturing Revenue by Application (2021-2032)
- 10.4.1 China Contract Pharmaceutical Manufacturing Revenue by Application (2021-2026)
- 10.4.2 China Contract Pharmaceutical Manufacturing Revenue by Application (2027-2032)
- 10.5 China Contract Pharmaceutical Manufacturing Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Contract Pharmaceutical Manufacturing Revenue (2021-2032)
- 11.2 Asia Contract Pharmaceutical Manufacturing Revenue by Type (2021-2032)
- 11.2.1 Asia Contract Pharmaceutical Manufacturing Revenue by Type (2021-2026)
- 11.2.2 Asia Contract Pharmaceutical Manufacturing Revenue by Type (2027-2032)
- 11.3 Asia Contract Pharmaceutical Manufacturing Revenue Share by Type (2021-2032)
- 11.4 Asia Contract Pharmaceutical Manufacturing Revenue by Application (2021-2032)
- 11.4.1 Asia Contract Pharmaceutical Manufacturing Revenue by Application (2021-2026)
- 11.4.2 Asia Contract Pharmaceutical Manufacturing Revenue by Application (2027-2032)
- 11.5 Asia Contract Pharmaceutical Manufacturing Revenue Share by Application (2021-2032)
- 11.6 Asia Contract Pharmaceutical Manufacturing Revenue by Country
- 11.6.1 Asia Contract Pharmaceutical Manufacturing Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Contract Pharmaceutical Manufacturing Revenue by Country (2021-2026)
- 11.6.3 Asia Contract Pharmaceutical Manufacturing Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Contract Pharmaceutical Manufacturing Revenue (2021-2032)
- 12.2 SAMEA Contract Pharmaceutical Manufacturing Revenue by Type (2021-2032)
- 12.2.1 SAMEA Contract Pharmaceutical Manufacturing Revenue by Type (2021-2026)
- 12.2.2 SAMEA Contract Pharmaceutical Manufacturing Revenue by Type (2027-2032)
- 12.3 SAMEA Contract Pharmaceutical Manufacturing Revenue Share by Type (2021-2032)
- 12.4 SAMEA Contract Pharmaceutical Manufacturing Revenue by Application (2021-2032)
- 12.4.1 SAMEA Contract Pharmaceutical Manufacturing Revenue by Application (2021-2026)
- 12.4.2 SAMEA Contract Pharmaceutical Manufacturing Revenue by Application (2027-2032)
- 12.5 SAMEA Contract Pharmaceutical Manufacturing Revenue Share by Application (2021-2032)
- 12.6 SAMEA Contract Pharmaceutical Manufacturing Revenue by Country
- 12.6.1 SAMEA Contract Pharmaceutical Manufacturing Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Contract Pharmaceutical Manufacturing Revenue by Country (2021-2026)
- 12.6.3 SAMEA Contract Pharmaceutical Manufacturing Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst